^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Lung Cancer
    Title:

    Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: a multicenter retrospective study

    Published date:
    07/24/2023
    Excerpt:
    For ERBB2-mutant patients, the mPFS was 5.9 months, and Chemo+Immuno and Chemo+Antiangio both achieved longer mPFS than TKI (12.9 vs 2.9 months, HR: 0.15, 95%CI: 0.03-0.68, P=0.005; 7.1 vs 2.9 months, HR: 0.50, 95%CI: 0.29-0.88, P=0.009, respectively).
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1016/j.lungcan.2023.107315